Treat and Extend Therapy Using Intravitreal Aflibercept (IAI) for Previously Treated Patients Exiting the Wet Age-related Macular Degeneration Extension Study (0910) [EXTENSION OF 700242217]

Trial Profile

Treat and Extend Therapy Using Intravitreal Aflibercept (IAI) for Previously Treated Patients Exiting the Wet Age-related Macular Degeneration Extension Study (0910) [EXTENSION OF 700242217]

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 03 Nov 2015

At a glance

  • Drugs Aflibercept (Primary)
  • Indications Wet age-related macular degeneration
  • Focus Therapeutic Use
  • Acronyms RANGE
  • Most Recent Events

    • 03 Nov 2015 Last checked against ClinicalTrials.gov record
    • 29 Oct 2015 Planned End Date changed from 1 Jul 2015 to 1 Jul 2016 as reported by ClinicalTrials.gov.
    • 29 Oct 2015 Planned primary completion date changed to 1 Mar 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top